The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an impressive impact on the treatment of multiple myeloma. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of multiple myeloma therapy, several agents entered the market in 2019 and 2020 (namely, Blenrep, Xpovio, and Sarclisa), and the late-phase pipeline remains buoyant. Indeed, immense clinical and commercial potential remains for therapies with improved efficacy and novel mechanisms of action that can fulfill the needs of underserved patient segments, such as smoldering multiple myeloma.

Questions Answered

  • What is the size of the drug-treatable multiple myeloma population, and will drug-treatment rates vary over time?
  • How will the use of Revlimid and Velcade change over the forecast period? What impact will their expected generic erosion have on the multiple myeloma market?
  • What are thought leaders’ opinions of novel agents such as CAR T-cell therapies and the SC formulation of Darzalex?
  • What are the key drivers of and constraints in the multiple myeloma therapy market? How will the entry of new agents shape the market?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Scope

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and country-specific surveys with 210 hematologist-oncologists treating multiple myeloma.

Epidemiology: Incidence of multiple myeloma by country, segmented by symptom.

Emerging therapies: Phase III/PR: 3 drugs; coverage of select Phase I and II products.

Table of contents

  • Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
        • November 2020
      • Q3 2020
        • September 2020
      • Q2 2020
        • June 2020
      • Q1 2020
        • March 2020
    • Key Findings
      • Multiple Myeloma - Key Findings
        • March 2020
    • Market Outlook
      • Key Findings
        • Major-Market Share of Drug Classes for Multiple Myeloma: 2019
        • Major-Market Share of Drug Classes for Multiple Myeloma: 2029
        • Major-Market Sales of Key Drugs in the Multiple Myeloma Market: 2019-2029
        • Major-Market Multiple Myeloma Sales by Line of Therapy: 2019-2029
        • Drug-Treatable Population Share and Major-Market Sales Share in Multiple Myeloma: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share in Multiple Myeloma: 2029
        • Population Positioning of Therapies in Multiple Myeloma
        • Multiple Myeloma SWOT Analysis
      • COVID-19 Areas of potential forecast impact
        • COVID-19: Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
        • Expert Insight: Impact of COVID-19 on Treatment Practices in Multiple Myeloma
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Multiple Myeloma?
        • What Factors Are Constraining the Market for Multiple Myeloma?
      • Segment-Specific Trends
        • Smoldering Multiple Myeloma
        • First-Line Transplant-Eligible Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in First-Line Transplant-Eligible Multiple Myeloma in the United States: 2019-2029
        • First-Line Transplant-Ineligible Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in First-Line Transplant-Ineligible Multiple Myeloma in the United States: 2019-2029
        • Relapsed/Refractory Multiple Myeloma
        • Patient-Share Dynamics of Key Regimens in Second-Line Multiple Myeloma in the United States: 2019-2029
        • Patient-Share Dynamics of Key Regimens in Third-Line Multiple Myeloma in the United States: 2019-2029
        • Patient-Share Dynamics of Key Regimens in Fourth-Line Multiple Myeloma in the United States: 2019-2029
        • Patient-Share Dynamics of Key Regimens in Fifth- to Seventh-Line Multiple Myeloma in the United States: 2019-2029
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Clinical Manifestations of Multiple Myeloma
      • Disease Pathophysiology
        • Overview
        • Plasma Cell and Myeloma Cell Process
      • Risk Factors
        • Select Risk Factors Associated with Multiple Myeloma
      • Staging and Classification
        • Classification of Multiple Myeloma
        • Revised IMWG Classification Criteria of Multiple Myeloma
        • Staging of Multiple Myeloma
        • Durie-Salmon Staging System for Multiple Myeloma
        • International Staging System for Multiple Myeloma
      • Key Pathways and Drug Targets
        • Drug Targets and Potential Therapies for Multiple Myeloma
        • Cell-Surface Molecules on Myeloma Cells and Bone Marrow Stromal Cells
        • IMiD-Mediated Disruption of Myeloma Cell-Microenvironment Interactions
        • The Potentially Synergistic Antitumor Effects of Proteasome and Aggresome Pathways
        • Biology of Selective Inhibitors of Nuclear Export (SINE)
        • Biology of B-Cell Maturation Antigen (BCMA)
        • Aminopeptidases in Apoptosis of Myeloma Cells
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Disease Definition
        • Methods
        • Sources Used for Diagnosed Incidence of Multiple Myeloma
        • Diagnosed Incident Cases of Multiple Myeloma: 2019-2029
        • Disease Definition
        • Methods
        • Sources Used for Symptomatic Distribution of Multiple Myeloma
        • Diagnosed Incident Cases of Multiple Myeloma by Symptoms: 2019-2029
        • Disease Definition
        • Methods
        • Sources Used for Asymptomatic Multiple Myeloma Progression to Symptomatic Multiple Myeloma
        • Asymptomatic Cases Progressing to Symptomatic Cases of Multiple Myeloma in the Major Pharmaceutical Markets: 2019-2029
        • Drug-Treatable Cases of Multiple Myeloma: 2019-2029
        • Multiple Myeloma Patient Flow
        • Drug-Treated Cases of Multiple Myeloma: 2019-2029
    • Current Treatment
      • Key Findings
        • Treatment Goals
          • Key Endpoints Used in Clinical Trials for Multiple Myeloma
        • Key Current Therapies
          • Overview
          • Mechanism of Action of Key Current Drug Classes Used for Multiple Myeloma
          • Current Treatments Used for Multiple Myeloma
          • Market Events Impacting the Use of Key Current Therapies in Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Thalomid / Thalidomide / Thaled for the Treatment of Multiple Myeloma
          • Expert Insights: Thalomid / Thalidomide / Thaled
          • Key Results from Select Clinical Trials Investigating Revlimid for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Revlimid
          • Key Ongoing Clinical Trials of Revlimid in the Treatment of Multiple Myeloma
          • Expert Insights: Revlimid
          • Key Results from Select Clinical Trials Investigating Pomalyst / Imnovid for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Pomalyst / Imnovid
          • Key Ongoing Clinical Trials Investigating Pomalyst / Imnovid in the Treatment of Multiple Myeloma
          • Expert Insights: Pomalyst / Imnovid
          • Key Results from Select Clinical Trials Investigating Velcade for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Velcade
          • Key Ongoing Clinical Trials Investigating Velcade in the Treatment of Multiple Myeloma
          • Expert Insights: Velcade
          • Key Results from Select Clinical Trials Investigating Kyprolis for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Kyprolis
          • Key Ongoing Clinical Trials of Kyprolis in the Treatment of Multiple Myeloma
          • Expert Insights: Kyprolis
          • Key Results from Select Clinical Trials Investigating Ninlaro for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Ninlaro
          • Key Ongoing Clinical Trials of Ninlaro in the Treatment of Multiple Myeloma
          • Expert Insights: Ninlaro
          • Key Results from Select Clinical Trials Investigating Farydak for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Farydak
          • Key Ongoing Clinical Trials Investigating Farydak in the Treatment of Multiple Myeloma
          • Expert Insights: Farydak
          • Key Results from Select Clinical Trials Investigating Empliciti for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Empliciti
          • Key Ongoing Clinical Trials Investigating Empliciti in the Treatment of Multiple Myeloma
          • Expert Insights: Empliciti
          • Key Results from Select Clinical Trials Investigating Darzalex for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Darzalex
          • Key Ongoing Clinical Trials of Darzalex in the Treatment of Multiple Myeloma
          • Expert Insights: Darzalex
          • Sarclisa
          • Key Results from Select Clinical Trials Investigating Sarclisa for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Sarclisa
          • Key Ongoing Clinical Trials of Sarclisa in the Treatment of Multiple Myeloma
          • Expert Insights: Sarclisa
          • Xpovio / Nexpovio
          • Key Results from Select Clinical Trials Investigating Xpovio / Nexpovio for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Xpovio / Nexpovio
          • Key Ongoing Clinical Trials of Xpovio / Nexpovio in the Treatment of Multiple Myeloma
          • Expert Insights: Xpovio / Nexpovio
          • Key Results from Select Clinical Trials Investigating Blenrep for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Blenrep
          • Key Ongoing Clinical Trials of Blenrep in the Treatment of Multiple Myeloma
          • Expert Insights: Blenrep
          • Key Results from Select Clinical Trials Investigating Pepaxto for the Treatment of Multiple Myeloma
          • Ongoing Clinical Development of Pepaxto
          • Key Ongoing Clinical Trials of Pepaxto in the Treatment of Multiple Myeloma
          • Expert Insights: Pepaxto (melflufen)
        • Medical Practice
          • Asymptomatic Multiple Myeloma
          • First-Line Transplant-Eligible Multiple Myeloma
          • First-Line Transplant-Ineligible Multiple Myeloma
          • Relapsed/Refractory Multiple Myeloma
          • Country-Specific Multiple Myeloma Treatment Guidelines
          • Patient Characteristics Influencing Drug Selection in Multiple Myeloma
          • Treatment Decision Tree for Multiple Myeloma: United States
          • Treatment Decision Tree for Multiple Myeloma: Europe
          • Treatment Decision Tree for Multiple Myeloma: Japan
      • Unmet Need Overview
        • Attainment of Unmet Needs
          • Current and Future Attainment of Unmet Needs in Multiple Myeloma
          • Top Unmet Needs in Multiple Myeloma: Current and Future Attainment
      • Emerging Therapies
        • Key Findings
          • Pipeline Trends for Multiple Myeloma
        • Key Emerging Therapies
          • Key Therapies in Development for Multiple Myeloma
          • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Venclexta / Venclyxto for the Treatment of Multiple Myeloma
          • Key Ongoing Clinical Trials of Venclexta / Venclyxto in the Treatment of Multiple Myeloma
          • Analysis of the Clinical Development Program for Venclexta / Venclyxto
          • Expert Insights: Venclexta / Venclyxto
          • Expectations for Market Authorization and Sales Opportunity of Venclexta / Venclyxto in Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Idecabtagene Vicleucel for the Treatment of Multiple Myeloma
          • Key Ongoing Clinical Trials Investigating Idecabtagene Vicleucel in the Treatment of Multiple Myeloma
          • Analysis of the Clinical Development Program for Idecabtagene Vicleucel
          • Expert Insights: Idecabtagene Vicleucel
          • Expectations for Launch and Sales Opportunity of Idecabtagene Vicleucel in Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Ciltacabtagene Autoleucel for the Treatment of Multiple Myeloma
          • Key Ongoing Clinical Trials Investigating Ciltacabtagene Autoleucel in the Treatment of Multiple Myeloma
          • Analysis of the Clinical Development Program for Ciltacabtagene Autoleucel
          • Expert Insights: Ciltacabtagene Autoleucel
          • Expectations for Launch and Sales Opportunity of Ciltacabtagene Autoleucel in Multiple Myeloma
          • Key Results from Select Clinical Trials Investigating Elranatamab (PF-06863135) for the Treatment of Multiple Myeloma
          • Analysis of the Clinical Development Program for Elranatamab
          • Key Ongoing Clinical Trials Investigating Elranatamab in the Treatment of Multiple Myeloma
          • Expectations for Launch and Sales Opportunity of Elranatamab in Multiple Myeloma
        • Early-Phase Pipeline Analysis
          • Select Compounds in Early-Phase Development for Multiple Myeloma
      • Access and Reimbursement Overview
        • Region-Specific Reimbursement Practices
          • Key Market Access Considerations in Multiple Myeloma: United States
          • General Reimbursement Environment: United States
          • Key Market Access Considerations in Multiple Myeloma: EU5
          • General Reimbursement Environment: EU5
          • Key Market Access Considerations in Multiple Myeloma: Japan
          • General Reimbursement Environment: Japan
      • Appendix
        • Key Abbreviations Related to Multiple Myeloma
        • Brands, Marketers, and Generic Availability of Current Therapies Used for Multiple Myeloma by Market
        • Multiple Myeloma Bibliography

    Author(s): Snigdha Gupta, Ph.D.; Ullas Ulahannan

    Snigdha Gupta, Ph.D., is a principal analyst on the Oncology team at DRG, part of Clarivate. She has worked on multiple oncology indications, including non-small-cell lung cancer and multiple myeloma. She holds a Ph.D. in infectious diseases from the Indian Institute of Chemical Biology at Jadavpur University in Kolkata. She pursued a postdoctoral fellowship at the Mucosal Immunology Lab of the National Institute of Immunology in New Delhi and has been published in several peer-reviewed journals.

    Ullas Ulahannan, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.


    Related Reports

    Multiple Myeloma - Epidemiology - Emerging Markets

    DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in...

    View Details

    Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

    DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

    View Details

    Multiple Myeloma - Epidemiology - Mature Markets

    DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We re...

    View Details

    Multiple Myeloma | Disease Landscape and Forecast | G7 | 2020

    The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an impressive impact on the treatment of mu...

    View Details